Tumor necrosis factor alpha and gamma interferon, but not hemorrhage or pathogen burden, dictate levels of protective fibrin deposition during infection

Infection and Immunity

Volumn 74, Issue 2, 2006, Pages 1181-1188

  Mullarky, Isis K ^a   Szaba, Frank M ^a   Berggren, Kiera N ^a   Kummer, Lawrence W ^a   Wilhelm, Lindsey B ^a   Parent, Michelle A ^a   Johnson, Lawrence L ^a   Smiley, Stephen T ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBRIN DEPOSITION; INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE REPAIR; TOXOPLASMA; TOXOPLASMOSIS; WILD TYPE;

ACUTE DISEASE; ANIMALS; FIBRIN; GENE EXPRESSION REGULATION; HEMORRHAGE; HUMANS; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; TOXOPLASMA; TOXOPLASMOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31844453974     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.74.2.1181-1188.2006     Document Type: Article

References (58)

1. Ahrenholz, D. H., and R. L. Simmons. 1980. Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 88:41-47.
2. Bauer, K. A., H. ten Cate, S. Barzegar, D. R. Spriggs, M. L. Sherman, and R. D. Rosenberg. 1989. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 74:165-172.
3. Bevilacqua, M. P., J. S. Pober, G. R. Majeau, W. Fiers, R. S. Cotran, and M. A. Gimbrone, Jr. 1986. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin I. Proc. Natl. Acad. Sci. USA 83:4533-4537.
4. Brett, J., H. Gerlach, P. Nawroth, S. Steinberg, G. Godman, and D. Stern. 1989. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J. Exp. Med. 169:1977-1991.
5. Clauss, M., C. Sunderkotter, B. Sveinbjornsson, S. Hippenstiel, A. Willuweit, M. Marino, E. Haas, R. Seljelid, P. Scheurich, N. Suttorp, M. Grell, and W. Risau. 2001. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood 97:1321-1329.
6. Conway, E. M., R. Bach, R. D. Rosenberg, and W. H. Konigsberg. 1989. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb. Res. 53:231-241.
7. Del Prete, G., M. De Carli, R. M. Lammel, M. M. D'Elios, K. C. Daniel, B. Giusti, R. Abbate, and S. Romagnani. 1995. Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 86:250-257.
8. Denkers, E. Y., and R. T. Gazzinelli. 1998. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11:569-588.
9. Dosne, A. M., F. Dubor, F. Lutcher, M. Parant, and L. Chedid. 1988. Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat. Thromb. Res. (Suppl.) 8:115-122.
10. Drew, A. F., H. Liu, J. M. Davidson, C. C. Daugherty, and J. L. Degen. 2001. Wound-healing defects in mice lacking fibrinogen. Blood 97:3691-3698.
11. Dunn, D. L., and R. L. Simmons. 1982. Fibrin in peritonitis. III. The mechanism of bacterial trapping by polymerizing fibrin. Surgery 92:513-519.
12. Echtenacher, B., K. Weigl, N. Lehn, and D. N. Mannel. 2001. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect. Immun. 69:3550-3555.
13. Flick, M. J., X. Du, D. P. Witte, M. Jirouskova, D. A. Soloviev, S. J. Busuttil, E. F. Plow, and J. L. Degen. 2004. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J. Clin. Invcstig. 113:1596-1606.
14. Friedl, J., M. Puhlmann, D. L. Bartlett, S. K. Libutti, E. N. Turner, M. F. Gnant, and H. R. Alexander. 2002. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100:1334-1339.
15. Furie, B., and B. C. Furie. 1988. The molecular basis of blood coagulation. Cell 53:505-518.
16. Gallicchio, M., P. Hufnagl, J. Wojta, and P. Tipping. 1996. IFN-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J. Immunol. 157:2610-2617.
17. Gavrilescu, L. C., B. A. Butcher, L. Del Rio, G. A. Taylor, and E. Y. Denkers. 2004. STAT1 is essential for antimicrobial effector function hut dispensable for gamma Interferon production during Toxoplasma gondii infection. Infect. Immun. 72:1257-1264.
18. Gazzinelli, R. T., M. Wysocka, S. Hayashi, E. Y. Denkers, S. Hieny, P. Caspar, G. Trinchieri, and A. Sher. 1994. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 153:2533-2543.
19. Gibson, F. C., III, A. B. Onderdonk, D. L. Kasper, and A. O. Tzianabos. 1998. Cellular mechanism of intraabdominal abscess formation by Bacteroides fragilis. J. Immunol. 160:5000-5006.
20. Gluszko, P., A. Undas, S. Amenta, A. Szczeklik, and A. H. Schmaier. 1994. Administration of gamma Interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor. J. Lab. Clin. Med. 123:232-240.
21. Halloran, P. F., M. Afrouzian, V. Ramassar, J. Urmson, L. F. Zhu, L. M. Helms, K. Solez, and N. M. Kneteman. 2001. Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis. Am. J. Pathol. 158:215-226.
22. Halloran, P. F., L. W. Miller, J. Urmson, V. Ramassar, L. F. Zhu, N. M. Kneteman, K. Solez, and M. Afrouzian. 2001. IFN-gamma alters the pathology of graft rejection: protection from early necrosis. J. Immunol. 166:7072-7081.
23. Johnson, L. L., K. N. Berggren, F. M. Szaba, W. Chen, and S. T. Smiley. 2003. Fibrin-mediated protection against infection-stimulated immunopathology. J. Exp. Med. 197:801-806.
24. Kasza, A., D. L. Kiss, S. Gopalan, W. Xu, R. E. Rydel, A. Koj, and T. Kordula. 2002. Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 in human astrocytes. J. Neurochem. 83:696-703.
25. Kinasewitz, G. T., S. B. Yan, B. Basson, P. Comp, J. A. Russell, A. Cariou, S. L. Um, B. Utterback, P. F. Laterre, and J. F. Dhainaut. 2004. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit. Care 8:R82-R90.
26. Levi, M., E. de Jonge, and T. van der Poll. 2004. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann. Med. 36:41-49.
27. Liesenfeld, O., H. Kang, D. Park, T. A. Nguyen, C. V. Parkhe, H. Watanabe, T. Abo, A. Sher, J. S. Remington, and Y. Suzuki. 1999. TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Parasite Immunol. 21:365-376.
28. Liesenfeld, O., J. Kosek, J. S. Remington, and Y. Suzuki. 1996. Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J. Exp. Med. 184:597-607.
29. Mathison, J. C., E. Wolfson, and R. J. Ulevitch. 1988. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Investig. 81:1925-1937.
30. McCabe, R. E., and J. S. Remington. 1990. Toxoplasma gondii, p. 2090-2103. In G. L. Mandell, R. G. Douglas, and J. E. Bennett (ed.), Principles and practices of infectious diseases, 3rd ed. Churchill Livingstone, Inc., New York, N. Y.
31. McRitchie, D. I., M. J. Girotti, M. F. Glynn, J. M. Goldberg, and O. D. Rotstein. 1991. Effect of systemic fibrinogen depletion on intraabdominal abscess formation. J. Lab. Clin. Med. 118:48-55.
32. Medcalf, R. L., E. K. Kruithof, and W. D. Schleuning. 1988. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J. Exp. Med. 168:751-759.
33. Moake, J. L. 2002. Thrombotic microangiopathies. N. Engl. J. Med. 347:589-600.
34. Moon, D. K., and C. L. Geczy. 1988. Recombinant IFN-gamma synergizes with lipopolysaccharide to induce macrophage membrane procoagulants. J. Immunol. 141:1536-1542.
35. Mullarky, I. K., F. M. Szaba, K. N. Berggren, M. A. Parent, L. W. Kummer, W. Chen, L. L. Johnson, and S. T. Smiley. 2005. Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. Infect. Immun. 73:3888-3895.
36. Musial, J., P. Gluszko, A. Undas, F. Mahdi, S. Kang, A. Szczeklik, and A. H. Schmaier. 1998. Gamma interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates C1 inhibitor. Thromb. Res. 89:253-261.
37. Nawroth, P. P., and D. M. Stern. 1986. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740-745.
38. Qiu, G., E. Gribbin, K. Harrison, N. Sinha, and K. Yin. 2003. Inhibition of gamma interferon decreases bacterial load in peritonitis by accelerating peritoneal fibrin deposition and tissue repair. Infect. Immun. 71:2766-2774.
39. Qiu, G., C. Wang, R. Smith, K. Harrison, and K. Yin. 2001. Role of IFN-gamma in bacterial containment in a model of intra-abdominal sepsis. Shock 16:425-429.
40. Ramana, C. V., M. P. Gil, R. D. Schreiber, and G. R. Stark. 2002. Stall-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol. 23:96-101.
41. Randall, T. D., F. E. Lund, M. C. Howard, and I. L. Weissman. 1996. Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells. Blood 87:4057-4067.
42. Rockey, D. C. 1999. Occult gastrointestinal bleeding. N. Engl. J. Med. 341:38-46.
43. Rotstein, O. D. 1992. Role of fibrin deposition in the pathogenesis of intraabdominal infection. Eur. J. Clin. Microbiol. Infect. Dis. 11:1064-1068.
44. Rotstein, O. D., and J. Kao. 1988. Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator. J. Infect. Dis. 158:766-772.
45. Scarpati, E. M., and J. E. Sadler. 1989. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J. Biol. Chem. 264:20705-20713.
46. Scharton-Kersten, T. M., T. A. Wynn, E. Y. Denkers, S. Bala, E. Grunvald, S. Hieny, R. T. Gazzinelli, and A. Sher. 1996. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157:4045-4054.
47. Schwager, I., and T. W. Jungi. 1994. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood 83:152-160.
48. Tapper, H., and H. Herwald. 2000. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood 96:2329-2337.
49. van der Poll, T., H. R. Buller, H. ten Cate, C. H. Wortel, K. A. Bauer, S. J. van Deventer, C. E. Hack, H. P. Sauerwein, R. D. Rosenberg, and J. W. ten Cate. 1990. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 322:1622-1627.
50. van der Poll, T., E. de Jonge, and M. Levi. 2001. Regulatory role of cytokines in disseminated intravascular coagulation. Semin. Thromb. Hemost. 27:639-651.
51. van der Poll, T., P. M. Jansen, K. J. Van Zee, M. B. Welborn III, I. de Jong, C. E. Hack, H. Loetscher, W. Lesslauer, S. F. Lowry, and L. L. Moldawer. 1996. Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 88:922-927.
52. van der Poll, T., M. Levi, H. R. Buller, S. J. van Deventer, J. P. de Boer, C. E. Hack, and J. W. ten Cate. 1991. Fibrinolytic response to tumor necrosis factor in healthy subjects. J. Exp. Med. 174:729-732.
53. van der Poll, T., M. Levi, S. J. van Deventer, H. ten Cate, B. L. Haagmans, B. J. Biemond, H. R. Buller, C. E. Hack, and J. W. ten Cate. 1994. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83:446-451.
54. van Gorp, E. C., C. Suharti, H. ten Cate, W. M. Dolmans, J. W. van der Meer, J. W. ten Cate, and D. P. Brandjes. 1999. Review: infectious diseases and coagulation disorders. J. Infect. Dis. 180:176-186.
55. van Hinsbergh, V. W., K. A. Bauer, T. Kooistra, C. Kluft, G. Dooijewaard, M. L. Shennan, and W. Nieuwenhuizen. 1990. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 76:2284-2289.
56. van Hinsbergh, V. W., T. Kooistra, M. A. Scheffer, J. Hajo van Bockel, and G. N. van Miujen. 1990. Characterization and fibrinorytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood 75:1490-1497.
57. van Hinsbergh, V. W., T. Kooistra, E. A. van den Berg, H. M. Princen, W. Fiers, and J. J. Emeis. 1988. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72:1467-1473.
58. Zinsser, H. H., and A. W. Pryde. 1952. Experimental study of physical factors, including fibrin formation, influencing the spread of fluids and small particles within and from the peritoneal cavity of the dog. Ann. Surg. 136:818-827.